Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Non-Current Deffered Revenue (2021 - 2025)

Historic Non-Current Deffered Revenue for Bolt Biotherapeutics (BOLT) over the last 5 years, with Q3 2025 value amounting to $2.0 million.

  • Bolt Biotherapeutics' Non-Current Deffered Revenue fell 4921.13% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 4921.13%. This contributed to the annual value of $3.6 million for FY2024, which is 6025.04% down from last year.
  • Per Bolt Biotherapeutics' latest filing, its Non-Current Deffered Revenue stood at $2.0 million for Q3 2025, which was down 4921.13% from $2.6 million recorded in Q2 2025.
  • Bolt Biotherapeutics' 5-year Non-Current Deffered Revenue high stood at $14.2 million for Q4 2021, and its period low was $2.0 million during Q3 2025.
  • In the last 5 years, Bolt Biotherapeutics' Non-Current Deffered Revenue had a median value of $9.6 million in 2023 and averaged $8.6 million.
  • Per our database at Business Quant, Bolt Biotherapeutics' Non-Current Deffered Revenue soared by 4877.56% in 2022 and then tumbled by 6237.1% in 2024.
  • Bolt Biotherapeutics' Non-Current Deffered Revenue (Quarter) stood at $14.2 million in 2021, then fell by 9.05% to $12.9 million in 2022, then dropped by 29.52% to $9.1 million in 2023, then tumbled by 60.25% to $3.6 million in 2024, then plummeted by 45.75% to $2.0 million in 2025.
  • Its Non-Current Deffered Revenue was $2.0 million in Q3 2025, compared to $2.6 million in Q2 2025 and $3.0 million in Q1 2025.